Vulvovaginal Atrophy: Clinical Trials

4 trials for Vulvovaginal Atrophy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 44Completed 4

Follow Vulvovaginal Atrophy: new trials by email Literature Review of Vulvovaginal Atrophy trials Research Report on Vulvovaginal Atrophy

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.
Estrogen, dehydroepiandrosterone, Estrogen + probiotics - Vulvovaginal Atrophy, Breast Cancer
Phase 4CompletedUniversity Hospital, Ghent312022-03-212026-08-13
Local DHEA and Estradiol on Dyspareunia in Postmenopausal Women
vaginal estradiol 10 μg, vaginal DHEA 6.5 mg - Vulvovaginal Atrophy, Genitourinary Syndrome of Menopause
Phase 4CompletedAngelica Lindén Hirschberg1702020-12-182024-12-17
Investigation of Non-inferiority of Treatment of Vulvovaginal Dryness With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol
WO2085 Moisturising Cream, Estriol Cream 0.1% - Vulvovaginal Atrophy
Phase 4CompletedDr. August Wolff GmbH & Co. KG Arzneimittel1722016-11-012017-07-14
Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
Ospemifene - Vulvovaginal Atrophy, Dyspareunia
Phase 4CompletedSue Goldstein102015-07-012019-04-02

Narrower conditions

Breast Neoplasms (1)  ·  Dyspareunia (1)

Broader conditions

Breast Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genital Diseases (1)  ·  Genital Diseases, Female (1)  ·  Genital Diseases, Male (1)  ·  Male Urogenital Diseases (1)  ·  Mental Disorders (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Sexual Dysfunction, Physiological (1)  ·  Sexual Dysfunctions, Psychological (1)  ·  Skin Diseases (1)  ·  Skin and Connective Tissue Diseases (1)  ·  Urogenital Diseases (1)

Interventions

Dehydroepiandrosterone (1)  ·  Estrogens (1)  ·  Ospemifene (1)  ·  Probiotics (1)

Sponsors

Angelica Lindén Hirschberg (1)  ·  Dr. August Wolff GmbH & Co. KG Arzneimittel (1)  ·  Sue Goldstein (1)  ·  University Hospital, Ghent (1)

Countries

Belgium (1)  ·  Germany (1)  ·  Sweden (1)  ·  Switzerland (1)  ·  United States (1)

Top investigators

Hans Verstraelen, MD, PhD (1)  ·  Irwin Goldstein, MD (1)  ·  Kirstin Deuble-Bente, MD (1)  ·  Prof. Christoph Abels, MD, PhD (1)  ·  Prof. Petra Stute, MD, PhD (1)

Results publications

PMID 29678557, PMID 41903372

NIH funding

2016 (1)